AIMT

AR101 (Palforzia)

Peanut Allergy

Stage (next event)

Expected Date

Quarterly Sales (Approved)

TBD

Catalyst Info & Data Links

We will not be following this anymore because AIMT was bought by Nestle 

Nestlé Completes Acquisition of Aimmune Therapeutics



TITLE: Quarterly Sales AR101 (Palforzia) in Peanut Allergy  (FDA-approved drug)


WHAT IS THE CATALYST EVENT?

  • Quarterly Sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • November 2020 (Est)


PRIOR DATA


PRESS RELEASE

MECHANISM OF ACTION/ RATIONALE

  • Although OIT is the most widely studied route of administration for food allergen immunotherapy, the precise mechanism of action underlying allergen desensitization is not fully understood. At least 2 temporally overlapping processes appear to be involved with AR101 treatment: 1) acute desensitization occurring over a period of weeks to months, and 2) immunomodulation occurring over a period of months to years.

  • The administration of gradually increasing amounts of allergen to allergic individuals during initial dose escalation results in the degranulation of mast cells and basophils bearing antigen-specific IgE bound to FcεR1, which in turn can result in allergy symptoms. The controlled release of mediators of inflammation by mast cells and basophils renders these cells temporarily refractory to subsequent antigen-mediated activation and granule release, leading to a state of acute desensitization. Desensitization is maintained by continued dosing with daily exposure during the up-dosing and maintenance periods.

  • Source - Sponsor Briefing Document/Allerginic Product Advisory Committee



COMPETITORS

  • Viaskin™ (by DBV Technologies)

MARKET

  • +15 million Americans have food allergies

  • +1.7 million children are believed to have a peanut allergy (In the U.S. alone)

  • Source

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

Amp Core Q2 '19 Report

FDA Accepts AIMT's Peanut Allergy Treatment BLA For Review

Amp Mid-Q1 '19 Update

AIMT Mid-Q1 '19 Update

Update on Aimmune Therapeutics Versus DBV Technologies Peanut Allergy-Related Candidate Treatments

AIMT and DBVT: Two different approaches to peanut allergy that are likely to eventually become comme

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon